HRQOL in Locally Advanced Thyroid Carcinoma

Launched by FUJIAN CANCER HOSPITAL · Apr 11, 2023

Keywords

ClinConnect Summary

This clinical trial is looking at how treatment with specific drugs, called tyrosine kinase inhibitors (TKIs), affects the quality of life for patients with locally advanced thyroid cancer. Researchers want to understand how these medications impact patients' daily lives and overall well-being. The study is currently recruiting participants between the ages of 18 and 70 who have been diagnosed with this type of cancer and are receiving TKI treatments.

If you or someone you know fits these criteria, you might be eligible to participate. Participants in the study can expect to fill out questionnaires to share their experiences and feelings about their health-related quality of life during treatment. It's important to note that pregnant or breastfeeding women, as well as individuals with certain recent health issues or other cancers, will not be able to join the trial. This research aims to provide valuable insights that could help improve care for future patients with thyroid cancer.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients age (18-70 year old)
• • Diagnosis of locally advanced thyroid cancer
• • Patient receiving TKI drugs.
• Exclusion Criteria:
• • pregnancy or breastfeeding women;
• • history of other malignant diseases, unstable angina, myocardial infarction, cerebral infarction or cerebral hemorrhage within 6 months; (3) patients missing questionnaires greater than 3 times.